Additional file 3: Table S2. of A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

FEV1 at Week 36 (all patients and biomarker subgroups). (XLSX 48 kb

Additional file 1: of A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

Figure S1. Study design. Figure S2. Pharmacokinetics of quilizumab in asthma patients. Figure S3. Effect of quilizumab on blood eosinophils (A, B) and FeNO (C, D) from baseline to Week 36. (PDF 422 kb